First Solar's Profit Engine Relies Heavily on Volatile Subsidies, Raising Durability Concerns

What happened

A Motley Fool article highlights doubts about the sustainability of First Solar's profits, which are heavily reliant on government subsidies like Section 45X credits. The DeepValue report confirms this dependence, with FY2025 recognizing $1.6 billion in credits and FY2026 gross margin guidance embedding $2.1 to $2.19 billion from subsidies out of a total $2.5 to $2.6 billion. Operational risks are evident from a 6.6 gigawatt termination due to customer breaches and a $50 million warranty liability for Series 7 issues, underscoring execution challenges beyond policy support. Net debookings in FY2025, with 7.4 gigawatts of gross bookings versus 8.3 gigawatts debooked, signal fragile demand and contracting instability. Despite a strong balance sheet with net cash, earnings power remains vulnerable to policy shifts and credit monetization haircuts.

Implication

First, any reduction in Section 45X eligibility or widening of monetization discounts could severely compress margins, given past credit sales with haircuts like $16 million on $312 million. Second, continued net debookings or another large termination would erode backlog confidence, limiting revenue visibility and growth prospects. Third, execution missteps, such as delays in the South Carolina facility or further warranty issues, could undermine ex-subsidy profitability. Fourth, while the net cash position provides some downside protection, it does not mitigate earnings volatility driven by policy-dependent credits. Fifth, aligning with the DeepValue report's 'WAIT' rating, investors should await clear evidence of stable net bookings and manageable credit haircuts before committing capital.

Thesis delta

The news article reinforces the existing thesis that First Solar's earnings are dominated by volatile subsidies, rather than introducing new data. It underscores the need for vigilance on booking stability and credit monetization, but does not shift the core recommendation to wait for clearer evidence before investing.